Skip to content
GLP-1 Savers
Menu

Head-to-head · Value Score

bmiMD vs TeleCareSpot

Two GLP-1 deals, scored on the same six factors. bmiMD lands a Value Score of 89, TeleCareSpot a 71. Here's who gives you the honest lower price — and where each one bites back.

★ Better value

bmiMD

#11 · Grade A · Great Deal

Est. first month

$99/mo

Save ~93% vs brand-name
Get this deal Full bmiMD review →
VS

TeleCareSpot

#231 · Grade C · Watch List

Est. first month

From $299/mo (all doses, plus a separate fee, compounded)

Save ~78% vs brand-name
Get this deal Full TeleCareSpot review →

The verdict

Better value: bmiMD

bmiMD takes it on Value Score, 89 to 71 an est. $99/mo first month, with no teaser step-up baked in. TeleCareSpot isn't out of it: Shoppers who want flat-priced, LegitScript-verified compounded semaglutide or tirzepatide with broad state coverage.

Our #1 overall:Neither of these is our top pick — that's CoreAge Rx (Value Score 93).See why →

Deal-by-deal

The numbers that decide it. Green ✓ marks the stronger side on each line.

DealbmiMDTeleCareSpot
Value Score89 (A)71 (C)
Est. first month$99/moFrom $299/mo (all doses, plus a separate fee, compounded)
Save vs brand-name~93%~78%
Semaglutide$99/moFrom $299/mo (all doses, plus a separate fee, compounded)
Tirzepatide$139/mo$399/mo
Both moleculesYesYes
PricingFlat — no step-upFlat — no step-up
CoverageAll 50 states48 states

Factor by factor

The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.

95
Lowest Real Price
52
bmiMD: 95. TeleCareSpot: 52.
84
No Teaser-Rate Bait
56
bmiMD: 84. TeleCareSpot: 56.
98
Nationwide Availability
88
bmiMD: 98. TeleCareSpot: 88.
94
Both Molecules
98
bmiMD: 94. TeleCareSpot: 98.
82
Easy Cancellation
95
bmiMD: 82. TeleCareSpot: 95.
70
Reputation
87
bmiMD: 70. TeleCareSpot: 87.

bmiMD

Sub-$100 semaglutide and a low $139 tirzepatide, flat and nationwide — a straight-up low-price play.

Why it's a deal

  • $99 flat semaglutide and a low $139 tirzepatide
  • Available in all 50 states
  • Both molecules priced up front

The fine print

  • Not LegitScript-certified — do your own pharmacy diligence
  • Thin public track record; no oral or brand-name option

TeleCareSpot

TeleCareSpot is a telehealth weight-loss platform offering doctor-prescribed compounded GLP-1s with flat, all-inclusive monthly pricing: compounded semaglutide at $299/month and tirzepatide at $399/month…

Why it's a deal

  • Flat, all-inclusive monthly pricing with no hidden fees — compounded semaglutide $299/month and tirzepatide $399/month, all doses included
  • Verifiable LegitScript certification (seal ID 45936855) plus HIPAA compliance and licensed US physicians
  • Multiple options: compounded semaglutide, tirzepatide, oral tirzepatide, and phentermine
  • DNA-calibrated dosing option that tailors the GLP-1 dose to how you metabolize it
  • Broad coverage in 47 states and DC, with free shipping and cancel-anytime plans

The fine print

  • Compounded medications are not FDA-approved — not brand Wegovy, Ozempic, Zepbound, or Mounjaro
  • Not available in Alaska, Mississippi, or New Jersey
  • The compounding pharmacy partner is not named
  • A separate weight-loss consultation fee applies (credited toward your medication package if approved)
  • Trustpilot rating and review counts (4.9, 14,000+) are self-stated on the site
Get the bmiMD deal Get the TeleCareSpot deal

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.

Neither one the right fit? Every program that outscores bmiMD is ranked on the bmiMD alternatives board, and the same list for the other side is on alternatives to TeleCareSpot.

More head-to-heads

← All comparisons

Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.